Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Condensed Consolidated Statements Of Operations        
Revenues            
Operating expenses:        
Amortization & depreciation 194 194 582 582
General and administrative 95,070 158,209 389,981 621,700
Total operating expenses 95,264 158,403 390,563 622,282
Gain (loss) from operations (95,264) (158,403) (390,563) (622,282)
Other income (expense):        
Gain (Loss) on fair value adjustment - derivatives 19,135 318,799 10,875 (70,498)
Gain on debt reversal    81,307    86,878
Interest expense (48,037) (25,014) (135,702) (91,071)
Interest expense - beneficial conversion feature (7,751) (19,501) (27,416) (152,993)
Total other income (expense) (36,653) 355,591 (152,243) (227,684)
Loss before provision for income taxes (131,917) 197,188 (542,806) (849,966)
Provision for income tax            
Net loss (131,917) 197,188 (542,806) (849,966)
Less: Net loss attributable to noncontrolling interest 1,021 618 3,388 5,803
Net loss attributable to TranBioTec, Inc. $ (130,896) $ 197,806 $ (539,418) $ (844,163)
Net loss per share (TransBiotec, Inc.)        
(Basic and fully diluted) $ 0.00 $ 0.01 $ (0.01) $ (0.03)
Weighted average number of common shares outstanding 41,884,034 33,431,576 37,810,366 32,005,187